Cognito Therapeutics Announces Proprietary Gamma Sensory Stimulation for 6-Months Reduces White Matter Atrophy in Alzheimer’s Disease Patients ...

Cognito beams up $73M for study of light-and-sound neuromod therapy to treat Alzheimer's By Andrea Park Mar 22, 2023 8:00am Cognito Therapeutics Alzheimer's disease neuromodulation neurostimulation ...

Cognito Therapeutics has delivered clinical data from its digital treatment for patients with Alzheimer’s disease—which relies on light and sound to stimulate specific electrical frequencies ...

Cognito’s OVERTURE trial demonstrated significant ‘time saved’ in functional and cognitive decline at both six and 18 months.

Cognito to Present Phase 2 OVERTURE Study Open-Label Extension Data Showing Safety and Durability of Treatment Benefits Over 18 Months at CTAD 2023 ...

CAMBRIDGE, Mass., July 17, 2025--Cognito Therapeutics to Present Five Abstracts at AAIC 2025 Highlighting Spectris™ Treatment in Alzheimer’s Disease ...

Alzheimer’s disease research at MIT spawned Cognito Therapeutics, a startup whose medical device uses light and sound to modulate electrical activity that supports brain health. The company’s ...

An experimental device developed by Cognito Therapeutics seeks to slow cognitive decline in Alzheimer’s patients using light and sound.